EP1515729B1 — Quaternised ammonium cyclodextrin compounds
Assigned to Novartis Pharma GmbH Austria · Expires 2008-02-20 · 18y expired
What this patent protects
Use of a compound of formula (I): wherein the symbol cyclodextrin ]n represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula per molecule of…
USPTO Abstract
Use of a compound of formula (I): wherein the symbol cyclodextrin ]n represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula per molecule of said compound; h is 0 or 1; R1 is a di-valent group selected from alkylene, hydroxy alkylene, halogeno alkylene, monocyclic aralkylene, cycloalkylene and phenylene; R2, R3 and R4 are each independently of one another a group selected from alkyl, cycloalkyl, aryl, aralkyl, and cycloheteryl; Xm- is a m-fold negatively charged anion; m is an integer being equal or greater than 1; and k is n/m in the preparation of an anti-infective medicament, as preservative and penetration enhancer.
Drugs covered by this patent
- Arthrotec (Diclofenac Sodium) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.